๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

โœ Scribed by Richard Hargreaves; Juan Camilo Arjona Ferreira; David Hughes; Jos Brands; Jeff Hale; Britta Mattson; Sandy Mills

Book ID
111400083
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
547 KB
Volume
1222
Category
Article
ISSN
0890-6564

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
โœ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

## Abstract ## BACKGROUND The neurokininโ€1 antagonist aprepitant (EMENDโ„ข; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapyโ€induced nausea and vomiting when it is given with a 5โ€hydroxytryptamineโ€3 receptor antagonist and dexamethasone. The current study sought to